MabPair

MabPair is a clinical-stage biotechnology company focused on developing a novel class of antibody therapeutics that can simultaneously target two different antigens using a proprietary platform. The company's lead candidate, bermekimab (formerly MABp1), is a first-in-class true human monoclonal antibody that targets Interleukin-1 alpha (IL-1α), a key driver of inflammation and tumor growth. MabPair's technology aims to improve the efficacy and safety of antibody treatments by enabling the production of two distinct antibodies from a single cell line, potentially simplifying manufacturing and enhancing therapeutic synergy. The company primarily targets oncology and chronic inflammatory indications where dual-pathway inhibition is expected to provide superior clinical outcomes.